Patent: 5,547,853
Summary for Patent: 5,547,853
| Title: | CD2-binding domain of lymphocyte function associated antigen 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Wallner; Barbara P. (Cambridge, MA), Miller; Glenn T. (Haverhill, MA), Rosa; Margaret D. (Winchester, MA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Biogen, Inc. (Cambridge, MA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | 07/940,861 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Claims: | see list of patent claims | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims summary: | United States Patent 5,547,853: Claim Scope, Expiration, CD2/LFA-3 Patent Landscape, and Commercial RelevanceUnited States Patent 5,547,853, directed to recombinant LFA-3/CD58 polypeptides and CD2-binding fusion proteins, was a foundational patent for the LFA-3-Ig technology later commercialized as alefacept (Amevive). Its claims cover defined LFA-3-derived peptides, encoding DNA, recombinant production systems, CD2-binding multimeric proteins, diagnostic uses, pharmaceutical compositions, and immunoglobulin Fc fusion proteins. The patent issued on August 20, 1996. Because it belongs to the pre-Uruguay Round Agreements Act patent-term framework, its ordinary term was generally 17 years from issuance, placing its expected expiration on August 20, 2013, absent a patent-term adjustment, extension, or terminal disclaimer that would alter the calculation. The claims therefore no longer provide enforceable U.S. patent exclusivity. What technology does United States Patent 5,547,853 cover?The patent claims engineered fragments of human LFA-3, also known as CD58, that bind CD2. CD2 is a cell-surface receptor expressed on T cells and natural killer cells. LFA-3/CD58 is its principal ligand on antigen-presenting and other cells. The patent is built around four technical concepts:
The claimed sequence architecture includes the central sequence:
This sequence is identified as SEQ ID NO:1 and is flanked by optional amino-terminal and carboxy-terminal sequences derived from LFA-3. The patent also claims shorter products, including SEQ ID NO:7:
The claims are functional as well as structural. The relevant product must be “capable of binding to CD2.” That limitation narrows the claims to molecules with demonstrated or legally provable CD2-binding activity, but it also creates potential litigation issues concerning assay conditions, binding affinity, and whether a sequence variant falls within the claimed functional boundary. How are the claims organized?
Claims 1 and 2 are genus claims. They permit optional amino-terminal methionine, optional LFA-3-derived amino-terminal sequence, the SEQ ID NO:1 core, and optional carboxy-terminal extensions. Claim 2 is narrower because it limits the flanking sequences to defined regions corresponding to SEQ ID NO:2 and SEQ ID NO:3. Claims 3 and 4 are more readily analyzed as sequence-defined species claims. Claim 4 is particularly narrow because it recites the exact 16-residue sequence of SEQ ID NO:7. Claims 19 through 23 are commercially important because they extend the invention from isolated peptides to fusion proteins. Claim 20 specifies an immunoglobulin Fc region, while claims 21 and 22 further define hinge, CH2, and CH3 components. Claim 23 identifies a particular sequence segment, amino acids 29-347 of SEQ ID NO:43. What are the strongest and weakest claim categories?Strongest claims: exact fusion constructs and disclosed DNAClaims 23, 28, and related claims directed to specifically disclosed sequences or plasmids are the most technically definite. A claim directed to a particular LFA-3-Ig sequence or named plasmid generally presents fewer claim-construction disputes than a broad functional genus. Claims 13 and 15 also have relatively concrete subject matter because they identify a nucleotide sequence or particular DNA inserts. Their practical value depends on whether the accused product uses the same sequence, a covered fragment, or a substantially different sequence encoding an equivalent CD2-binding domain. Broad but vulnerable claims: functional peptide generaClaims 1, 2, 9(a), 9(b), and 19(a)-(b) use a combination of:
This drafting approach creates potentially broad coverage, but it also raises written-description, enablement, indefiniteness, and claim-construction questions. The “portion thereof” language must be read in the context of the specified terminal direction and amino-acid range. A fragment is not automatically covered merely because it derives from LFA-3; it must satisfy the structural limitations and the CD2-binding requirement. Weaker commercial claims: compositions, kits, labeling, and generic production claimsClaims 6 through 8, 11, 12, 17, 18, 26, 27, and 29 through 34 are implementation claims. They are useful as fallback claims, but their practical value is usually lower than a direct product claim. A pharmaceutical composition claim does not necessarily capture every commercial formulation containing an LFA-3-derived molecule. The accused composition must include a covered polypeptide or fusion protein. A diagnostic-kit claim similarly depends on use of the specified CD2-binding reagent and the recited detection architecture. What does claim 35 add to the patent?Claim 35 covers a multimeric protein comprising:
This claim is directed to mixed multimeric architectures rather than a single LFA-3-Ig molecule. Its commercial relevance lies in avidity. Multiple CD2-binding domains can increase apparent binding strength and alter pharmacokinetics, valency, receptor clustering, and immune-cell engagement. The claim is also more structurally complex than claims 19 through 23. Litigation would likely focus on whether the accused molecule contains both required categories of components and whether the non-LFA-3 domain is part of a qualifying fusion protein. How does the patent relate to alefacept?Alefacept is a recombinant LFA-3-Ig fusion protein designed to bind CD2 and inhibit T-cell activation. The FDA approved Amevive in 2003 for the treatment of adults with moderate-to-severe chronic plaque psoriasis who were candidates for systemic therapy or phototherapy. The product consisted of an LFA-3-derived extracellular binding region fused to a human IgG1 Fc region.[2] The relationship between the patent and alefacept is direct at the platform level:
The patent should not be treated as establishing that every LFA-3-Ig molecule is identical to alefacept. Product coverage depends on the exact amino-acid sequence, domain boundaries, linker, Fc isotype, hinge configuration, glycosylation, and other structural details. When did United States Patent 5,547,853 lose exclusivity?The patent issued on August 20, 1996. Under the pre-URAA term applicable to many applications filed before June 8, 1995, the baseline term was 17 years from issuance. On that basis, the patent expired on August 20, 2013.
The patent’s expiration eliminates infringement risk based solely on this patent. It does not eliminate risk from later patents covering specific alefacept formulations, manufacturing processes, combination treatments, dosing regimens, or unrelated CD2-binding biologics. Patent expiration also does not eliminate regulatory exclusivity. Regulatory exclusivity is separate from patent rights. For alefacept, the original U.S. biologic approval was not protected indefinitely by the patent term, and the product was later withdrawn from the U.S. market. The FDA has not approved a biosimilar to alefacept.[2][3] What is the Orange Book status of this patent?United States Patent 5,547,853 is not expected to have an Orange Book listing because Orange Book patent listings principally concern approved small-molecule drug products and certain related products listed under FDA procedures. Alefacept was a biologic licensed under the Public Health Service Act rather than a conventional Orange Book small-molecule product. The relevant regulatory framework is the Biologics Price Competition and Innovation Act, which created the biosimilar pathway under section 351(k) of the Public Health Service Act. A biologic such as alefacept is generally evaluated through the Purple Book and biologics-licensure framework rather than through an Orange Book Paragraph IV certification process.[3][4] Are there Paragraph IV challenges to this patent?No current Paragraph IV challenge can create a meaningful market barrier based on this patent because the patent expired in 2013 and was not the type of active Orange Book-listed patent ordinarily addressed through a Paragraph IV certification. Paragraph IV litigation is primarily associated with abbreviated new drug applications for small-molecule products. A follow-on alefacept product would ordinarily raise biosimilar, interchangeability, reference-product exclusivity, and biologics-licensure issues rather than a conventional Paragraph IV dispute under the Hatch-Waxman framework.[3][4] What formulation patents protect alefacept or LFA-3-Ig products?The claims supplied for Patent 5,547,853 do not contain a detailed formulation patent. Claim 7 covers a pharmaceutical composition comprising a claimed polypeptide and pharmaceutically acceptable carrier. Claim 33 provides a corresponding composition claim for a fusion protein. These claims are broad composition claims, not detailed formulation claims. They do not specify:
A later patent could therefore protect a particular LFA-3-Ig formulation without being anticipated or exhausted by the generic composition language in claim 33. Conversely, the expired claim 33 cannot block a current product merely because it contains an LFA-3-Ig molecule and a pharmaceutically acceptable carrier. What manufacturing and intellectual-property barriers remain?The principal barriers after expiration are technical and regulatory rather than exclusivity based on Patent 5,547,853. Protein folding and disulfide formationLFA-3-derived fragments contain sequence-dependent structural requirements. Fusion to Fc changes folding, dimerization, glycosylation, aggregation, and clearance. A follow-on manufacturer must establish a reproducible product with a well-characterized higher-order structure. Glycosylation and product comparabilityA biosimilar or follow-on biologic must address glycosylation, charge variants, aggregates, host-cell proteins, residual DNA, potency, and immunogenicity. The primary sequence alone does not establish biosimilarity. CD2-binding potencyThe relevant biological activity is not limited to analytical identity. A manufacturer must show binding to CD2 and a suitable cell-based or biochemical potency relationship. Differences in Fc-mediated activity may be material, depending on the product design and intended mechanism. Cell-line and process controlsClaims 10 through 18 and 24 through 30 cover recombinant production concepts, but those claims are expired. Current barriers may arise from proprietary cell lines, process know-how, analytical methods, manufacturing capacity, or later process patents. How does this patent compare with later CD2 and LFA-3 patent estates?
The patent is therefore best characterized as an expired foundational platform patent. It is important for historical freedom-to-operate analysis and technology provenance, but it is not a current U.S. exclusionary right. What litigation and settlement issues remain relevant?A current litigation assessment would not treat infringement of Patent 5,547,853 as a viable standalone claim because the patent expired. Historical litigation could still matter for:
Patent expiration does not automatically terminate every contractual obligation. A settlement agreement, license, or supply agreement may contain terms extending beyond the patent term, although contractual restrictions cannot revive an expired patent right against third parties. How strong was the patent estate?Historically, the estate was strong at the platform level because it combined sequence, DNA, recombinant production, fusion-protein, multimer, pharmaceutical-composition, and diagnostic-use claims. This created multiple infringement theories against a commercial LFA-3-Ig product. Its principal weaknesses were claim breadth and functional dependence. The broad claims rely on optional terminal regions, “portions thereof,” and CD2-binding activity. Those limitations can create disputes over written description, enablement, indefiniteness, and claim construction. The narrow sequence and plasmid claims were more defensible but covered fewer design alternatives. Today, the estate’s practical strength is zero as an exclusionary patent right in the United States because the patent has expired. Its residual value is evidentiary and historical: it identifies the original disclosed sequences, constructs, vectors, and LFA-3-Ig architecture. What generic or biosimilar launch scenarios exist?A follow-on developer would likely pursue one of three paths:
The expired patent removes a foundational patent barrier. The remaining launch risks are likely to involve FDA requirements, clinical or pharmacodynamic comparability, immunogenicity, manufacturing validation, and any later patent covering a specific product or use. Key Takeaways
FAQsIs Patent 5,547,853 still enforceable against an LFA-3-Ig product?No. The patent’s ordinary term expired in 2013, so it cannot independently block a current U.S. LFA-3-Ig product. Does using an IgG1 Fc region avoid Patent 5,547,853?No avoidance analysis is necessary for the expired patent. For a later patent, the answer would depend on the exact LFA-3 sequence, Fc sequence, linker, formulation, and manufacturing process. Did Patent 5,547,853 claim the full-length CD58 protein?The supplied claims primarily target defined CD2-binding fragments and fusion proteins containing those fragments. They should not be read as a blanket claim to every full-length CD58 molecule. Is alefacept a small-molecule generic or a biosimilar product?Alefacept is a recombinant biologic. A follow-on product would generally be evaluated under the biologics framework, not as a conventional small-molecule generic under an abbreviated new drug application. Can a later patent still create launch risk after Patent 5,547,853 expires?Yes. Later patents may cover specific formulations, dosing regimens, treatment indications, manufacturing processes, cell lines, purification methods, or modified CD2-binding fusion proteins. References
More… ↓ |
Details for Patent 5,547,853
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Astellas Pharma Us, Inc. | AMEVIVE | alefacept | For Injection | 125036 | January 30, 2003 | 5,547,853 | 2012-10-21 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 5,547,853
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | E193724 | ⤷ Start Trial |
| Australia | 1754092 | ⤷ Start Trial |
| Australia | 660981 | ⤷ Start Trial |
| Brazil | 1100443 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
